Livzon Pharmaceutical Group Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Livzon Pharmaceutical Group wird ein jährliches Gewinn- und Umsatzwachstum von 9.8% bzw. 7.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 16.1% betragen.

Wichtige Informationen

9.9%

Wachstumsrate der Gewinne

9.8%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.5%
Wachstumsrate der Einnahmen	7.6%
Zukünftige Eigenkapitalrendite	15.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	16 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26

Recent updates

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Jun 07

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 26

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Apr 21

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Mar 15

Gewinn- und Umsatzwachstumsprognosen

SZSE:000513 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	15,167	2,589	N/A	4,009	5
12/31/2025	14,188	2,399	N/A	2,062	7
12/31/2024	13,297	2,157	N/A	4,633	6
3/31/2024	12,260	1,980	3,044	3,873	N/A
12/31/2023	12,430	1,954	2,428	3,249	N/A
9/30/2023	12,796	2,004	2,433	3,137	N/A
6/30/2023	13,017	2,026	1,827	2,574	N/A
3/31/2023	12,564	1,938	1,477	2,362	N/A
12/31/2022	12,630	1,909	1,833	2,773	N/A
9/30/2022	12,183	1,830	1,152	2,445	N/A
6/30/2022	12,131	1,731	1,236	2,654	N/A
3/31/2022	12,193	1,809	833	2,098	N/A
1/1/2022	12,064	1,776	593	1,902	N/A
9/30/2021	11,964	1,746	905	1,948	N/A
6/30/2021	11,661	1,773	1,036	1,962	N/A
3/31/2021	11,365	1,835	1,507	2,313	N/A
1/1/2021	10,520	1,715	1,514	2,161	N/A
9/30/2020	10,015	1,685	1,342	1,857	N/A
6/30/2020	9,541	1,569	1,272	1,682	N/A
3/31/2020	9,282	1,309	1,236	1,649	N/A
1/1/2020	9,385	1,303	1,369	1,767	N/A
9/30/2019	9,314	1,182	1,685	2,069	N/A
6/30/2019	9,235	1,188	1,830	2,244	N/A
3/31/2019	9,099	1,128	1,131	1,540	N/A
12/31/2018	8,861	1,082	793	1,268	N/A
9/30/2018	8,851	1,123	531	1,015	N/A
6/30/2018	8,821	4,558	423	850	N/A
3/31/2018	8,774	4,501	908	1,266	N/A
1/1/2018	8,531	4,429	N/A	1,316	N/A
9/30/2017	8,450	4,416	N/A	1,324	N/A
6/30/2017	8,142	879	N/A	1,419	N/A
3/31/2017	8,032	829	N/A	1,399	N/A
12/31/2016	7,652	784	N/A	1,279	N/A
9/30/2016	7,458	742	N/A	1,240	N/A
6/30/2016	7,289	691	N/A	1,002	N/A
3/31/2016	6,813	670	N/A	990	N/A
12/31/2015	6,621	623	N/A	928	N/A
9/30/2015	6,311	588	N/A	894	N/A
6/30/2015	6,031	566	N/A	748	N/A
3/31/2015	5,869	555	N/A	623	N/A
12/31/2014	5,544	516	N/A	717	N/A
9/30/2014	5,506	532	N/A	482	N/A
6/30/2014	5,085	519	N/A	458	N/A
3/31/2014	4,791	484	N/A	561	N/A
12/31/2013	4,619	488	N/A	440	N/A
9/30/2013	4,268	477	N/A	417	N/A
6/30/2013	4,221	472	N/A	444	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 000513Das prognostizierte Gewinnwachstum (9.8% pro Jahr) liegt über der Sparquote (2.9%).

Ertrag vs. Markt: 000513Die Erträge des Unternehmens (9.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (23.2% pro Jahr).

Hohe Wachstumserträge: 000513Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 000513Die Einnahmen des Unternehmens (7.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (14% pro Jahr).

Hohe Wachstumseinnahmen: 000513Die Einnahmen des Unternehmens (7.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 000513Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (16.1 %).

Livzon Pharmaceutical Group Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Price target decreased to CN¥42.19

Price target raised to CN¥51.22

Recent updates

We Think The Compensation For Livzon Pharmaceutical Group Inc.'s (SZSE:000513) CEO Looks About Right

Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024

Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection

Livzon Pharmaceutical Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Does Livzon Pharmaceutical Group (SZSE:000513) Have A Healthy Balance Sheet?

Livzon Pharmaceutical Group Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024

Is Now The Time To Put Livzon Pharmaceutical Group (SZSE:000513) On Your Watchlist?

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024

Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use

Livzon Pharmaceutical Group Inc. (SZSE:000513) announces an Equity Buyback for CNY 600 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. and Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives Acceptance of the Application for the Registration and Marketing Authorization of Triptorelin Acetate Microspheres for Injection

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Announces Board Appointments

Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) (Tax Included) for 2022, Payable on 04 July 2023

Livzon Pharmaceutical Group Inc. Approves Final Cash Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Livzon Pharmaceutical Group Inc. Announces Approval of Drug Marketing Authorisation Submitted by Livzon MABPharm Inc. for the Tocilizumab Injection Atvtia

Now 20% undervalued

Less than half of directors are independent

Third quarter 2022 earnings: Revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2022 Results on Oct 25, 2022

Price target decreased to CN¥42.19

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Livzon Pharmaceutical Group Inc. Receives Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. to Report First Half, 2022 Results on Aug 09, 2022

Livzon Pharmaceutical Announces on Drug Passing Consistency Evaluation for Generics

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2021

Less than half of directors are independent

Livzon Pharmaceutical Group Inc., Annual General Meeting, May 20, 2022

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on June 24, 2022

Livzon Pharmaceutical Group Inc. to Report Q1, 2022 Results on Apr 21, 2022

Full year 2021 earnings: EPS misses analyst expectations

Livzon Pharmaceutical Group Inc. Announces Ordinary Final Dividend for the Year Ended December 31, 2021, Payable on June 24, 2022

Investor sentiment improved over the past week

Livzon Pharmaceutical Group Inc. Obtains Approval Notice for Clinical Trial on Drug from National Medical Products Administration

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.44 in 3Q 2020)

Non-Executive Vice Chairman exercised options to buy CN¥239k worth of stock.

Livzon Pharmaceutical Group Inc. Announces Approval Notice for Clinical Trial on A Drug

Non-Executive Vice Chairman exercised options to buy CN¥408k worth of stock.

Second quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.64 in 2Q 2020)

Independent Non-Executive Director Zhihua Zheng has left the company

Independent Non-Executive Director Yun Xie has left the company

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2020, Payable on or Before June 25, 2021

Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of share transfer agreement to acquire a 40% stake in Tianjin Tongrentang Group Co., Ltd. from Tianjin Tasly Healthcare Industry Investment Partnership.

New 90-day low: CN¥34.73

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥38.49

Livzon Pharmaceutical Group Inc. announced that it expects to receive CNY 961.6 million in funding from YF Pharmab Limited

New 90-day low: CN¥42.15

President & Executive Director exercised options to buy CN¥2.7m worth of stock.

New 90-day low: CN¥46.34

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings beat expectations

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2020 Results on Oct 23, 2020

Price target raised to CN¥51.22

Earnings released

Livzon Pharmaceutical Group Inc. to Report First Half, 2020 Results on Aug 26, 2020

New 90-day high - CN¥56.12

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken